Xarelto

Type: Product
Name: Xarelto
First reported 17 mins ago - Updated 17 mins ago - 1 reports

Bayer/Johnson & Johnson to Expand Xarelto Label Further

Bayer ( BAYRY - Analyst Report ) and partner Johnson & Johnson ( JNJ - Analyst Report ) announced that they will be evaluating their anticoagulant product, Xarelto, in three new indications in new studies. The companies intend to expand their global ... [Published Zacks.com - 17 mins ago]
First reported 1 hour ago - Updated 21 mins ago - 2 reports

Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation

The use of Xarelto (known generically as rivaroxaban) and other new blood thinners is growing at a rapid pace, even as Xarelto lawsuits (http://www.xareltolawsuitcenter.com) continue to mount in courts around the U.S., Bernstein Liebhard LLP reports. ... [Published Bio-Medicine - 21 mins ago]
First reported 34 mins ago - Updated 34 mins ago - 1 reports

Janssen expands Xarelto research program

Janssen Research & Development and Bayer HealthCare announced the expansion of the EXPLORER research program for Xarelto with a series of new clinical trials in high-risk populations.The new studies will assess Factor Xa inhibitor Xarelto (rivaroxaban) ... [Published Orthopedics Today - 34 mins ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

ESC: Xarelto Safe for Cardioverting Afib

BARCELONA (MedPage Today) -- Switching atrial fibrillation patients awaiting elective cardioversion to rivaroxaban (Xarelto) was as safe as warfarin in that setting. ... [Published MedPageToday.com - medical news plus CME for ph ... - 3 hours ago]
First reported 15 hours ago - Updated 11 hours ago - 3 reports

Bayer HealthCare Announces Results From X-VeRT Study On Xarelto - Quick Facts

Bayer HealthCare, an unit of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), reported results from the X-VeRT study showing that once-daily Xarelto is an effective and well-tolerated alternative to dose-adjusted vitamin K antagonists or VKAs, ... [Published RTTNews.com - 15 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

BRIEF-Bayer says new data show Xarelto reduces risk of cardiovascular events

7:14am BSTBayer AgG* Says new phase IIIb data show xarelto reduces risk of cardiovascular events Further company coverage ... [Published Reuters UK - 15 hours ago]
Entities: Xarelto, Risk, Bayer AG
First reported Sep 01 2014 - Updated 18 hours ago - 1 reports

ANALYSIS-Pricing is key for new heart drugs challenging cheap generics

* Doctors expect healthcare providers to haggle over cost* Novartis's LCZ696 and PCSK9 drugs could treat millions* Analysts have forecast annual sales of $5 bln-plus for LCZ696* Some recent heart drugs have been used less widely than hopedBARCELONA, Sept ... [Published CNBC - Sep 01 2014]
First reported Aug 31 2014 - Updated Sep 01 2014 - 4 reports

Bayer HealthCare launches three new studies of Xarelto

:24 in Pharmaceutical Company Product News Bayer HealthCare has announced a new expansion of the global clinical development programme for Xarelto, its rivaroxaban-based oral Factor Xa inhibitor therapy. The three new studies will assess the safety and ... [Published Zenopa - Sep 01 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 6 reports

Bayer plans 3 new trials to support expanded use of stroke prevention drug Xarelto

FRANKFURT (Reuters) - Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines.Xarelto, which competes with the Eliquis pill developed by Bristol-Myers Squibb and ... [Published MedCity News - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Xarelto Bleeding Lawsuit Website Launched by National Products...

National products liability law firm investigates cases of internal bleeding and hemorrhagic stroke after using Xarelto The Onder Law Firm has recently launched a new Xarelto bleeding website offering information to persons who suffered serious bleeding ... [Published PRWeb - Aug 29 2014]
Entities: Xarelto, Lawsuit, Law Firm
First reported Aug 29 2014 - Updated Aug 29 2014 - 2 reports

Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs

GEMINI 1 & 2 ACS, a global indication-seeking clinical program, designed to evaluate rivaroxaban in patients who suffer from acute coronary syndrome (ACS). The program will launch with GEMINI 1 ACS, to investigate the benefits of the dual pathway strategy ... [Published Indianapolis Business Journal - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Birmingham, AL Law Firm Barclay Law LLC, Comments on Report about...

The lead attorney at Barclay Law LLC, of Birmingham, AL weighs in on a report about adverse events associated with the popular anticoagulant medication and legal options available to drug injury victims. Blood-thinning prescription medication Xarelto ... [Published PRWeb - Aug 28 2014]
Entities: Xarelto, Drugs, Birmingham

Quotes

"A brand new thing that saves lives should be adopted quickly" he said
...Dr Joerg Moeller, member of the Bayer HealthCare executive committee and head of global development, said: "We are committed to further investigate the potential benefits of rivaroxaban in areas of significant unmet medical need." Xarelto is the most broadly indicated novel oral anticoagulant and has already been approved for five indications in seven distinct areas of use...
...areas of significant unmet medical need," said Joerg Moeller, a member of the Bayer HealthCare executive committee and head of global development. "Rivaroxaban is already approved to prevent and treat more venous and arterial thromboembolic conditions than any other novel oral anticoagulant. However, areas of unmet medical need still exist where rivaroxaban could potentially benefit even more patients at risk of the serious and often life-threatening diseases caused by blood clots" Dr Moeller pointed out
"We really have just as many strokes due to undetermined causes as to atrial fibrillation" Frank Misselwitz, head of the Therapeutic Area Cardiovascular and Coagulation at Bayer HealthCare, told Reuters

More Content

All (194) | News (161) | Reports (0) | Blogs (29) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Popliteal Artery Occlusion After Total Knee Rep... [Published Vascular Disease Management - 15 mins ago]
Bayer/Johnson & Johnson to Expand Xarelto Label... [Published Zacks.com - 17 mins ago]
Xarelto Lawsuit News: Bernstein Liebhard LLP Co... [Published Bio-Medicine - 21 mins ago]
Janssen expands Xarelto research program [Published Orthopedics Today - 34 mins ago]
Xarelto Lawsuit News: Bernstein Liebhard LLP Co... [Published Benzinga.com - 1 hour ago]
ESC: Xarelto Safe for Cardioverting Afib [Published MedPageToday.com - medical news plus CME for ph ... - 3 hours ago]
Portola Pharmaceuticals to Present at the 2014 ... [Published EMoneyDaily - 9 hours ago]
Portola Pharmaceuticals to Present at the 2014 ... [Published TVNewsCheck - 9 hours ago]
X-VeRT: Rivaroxaban safe, effective in AF patie... [Published Orthopedics Today - 11 hours ago]
Bayer HealthCare Announces Results From X-VeRT ... [Published RTTNews.com - 15 hours ago]
BRIEF-Bayer says new data show Xarelto reduces ... [Published Reuters UK - 15 hours ago]
Once-Daily Xarelto® from Bayer Effective and We... [Published Bayer Corporate News - 15 hours ago]
New Data Show Once-Daily XARELTO® May Be an Alt... [Published PR Newswire: General Business - 15 hours ago]
ANALYSIS-Pricing is key for new heart drugs cha... [Published CNBC - Sep 01 2014]
Bayer HealthCare launches three new studies of ... [Published Zenopa - Sep 01 2014]
Janssen expands EXPLORER research program to ev... [Published PBR - News - Sep 01 2014]
Bayer to Launch Three New Xarelto Trials [Published PharmaAsia - Aug 31 2014]
New studies planned to further expand indicatio... [Published Pharma Letter - Aug 31 2014]
JTB Law Group, LLC Obtains Judgment for Maximum... [Published WGNT - Aug 30 2014]
Bayer plans 3 new trials to support expanded us... [Published MedCity News - Aug 29 2014]
Health Care Down as Traders Bet on Growth Areas... [Published 4 Traders - Aug 29 2014]
Xarelto Bleeding Lawsuit Website Launched by Na... [Published PRWeb - Aug 29 2014]
Dr. Ron Noy recognized as Pinnacle Professional... [Published News-Medical.Net - Aug 29 2014]
Germany's Bayer to launch three new Xarelto tri... [Published DailyMe.Com - Aug 29 2014]
Bayer Aims to Expand Xarelto Use Despite Known ... [Published Reliance Trust - Aug 29 2014]
Bayer Aims to Expand Xarelto Use Despite Known ... [Published SBWire - Aug 29 2014]
UPDATE 1-Germany's Bayer to launch three new Xa... [Published Reuters - Aug 29 2014]
Janssen Expands EXPLORER Global Cardiovascular ... [Published Indianapolis Business Journal - Aug 29 2014]
Germany's Bayer to launch three new Xarelto trials [Published Reuters UK - Aug 29 2014]
Janssen Expands EXPLORER Global Cardiovascular ... [Published PR Newswire: General Business - Aug 29 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ESC: Xarelto Safe for Cardioverting Afib [Published MedPageToday.com - medical news plus CME for ph ... - 3 hours ago]
BARCELONA (MedPage Today) -- Switching atrial fibrillation patients awaiting elective cardioversion to rivaroxaban (Xarelto) was as safe as warfarin in that setting. ...
Once-Daily Xarelto® from Bayer Effective and We... [Published Bayer Corporate News - 15 hours ago]
X-VeRT is the first prospective study of a novel oral anticoagulant in patients with atrial fibrillation who undergo cardioversion / X-VeRT provides important information on the utility and practical advantages of Xarelto in early and delayed cardioversion ...
New Data Show Once-Daily XARELTO® May Be an Alt... [Published PR Newswire: General Business - 15 hours ago]
BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today results from the X-VeRT trial, demonstrating once-daily XARELTO® (rivaroxaban) may be an alternative ...
Janssen expands EXPLORER research program to ev... [Published PBR - News - Sep 01 2014]
Janssen Research & Development (Janssen) and its development partner, Bayer HealthCare, have announced the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. ...
Janssen Expands EXPLORER Global Cardiovascular ... [Published PR Newswire: General Business - Aug 29 2014]
RARITAN, N.J., Aug. 29, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO® (rivaroxaban) to ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Keller Rohrback L.L.P. Investigates Life-Threat... [Published GlobeNewswire: Acquisitions News - Aug 26 2014]
Keller Rohrback L.L.P. Investigates Allegations... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.